DrugPatentWatch Database Preview
BAVENCIO Drug Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
Summary for Tradename: BAVENCIO
| Patents: | 24 |
| Applicants: | 1 |
| BLAs: | 2 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for BAVENCIO |
Recent Clinical Trials for BAVENCIO
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Southwest Oncology Group | Phase 2 |
| National Cancer Institute (NCI) | Phase 1/Phase 2 |
| Astellas Pharma Inc | Phase 2 |
Patent Text Search: US Patents for BAVENCIO
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emd Serono Inc | BAVENCIO | avelumab | INJECTABLE;INJECTION | 761049 | 001 | 2017-04-25 | Start Trial | Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) | 2035-06-26 | RX | Orphan | search |
| Emd Serono Inc | BAVENCIO | avelumab | INJECTABLE;INJECTION | 761049 | 001 | 2017-04-25 | Start Trial | ModernaTX, Inc. (Cambridge, MA) | 2035-12-23 | RX | Orphan | search |
| Emd Serono Inc | BAVENCIO | avelumab | INJECTABLE;INJECTION | 761049 | 001 | 2017-04-25 | Start Trial | ModernaTX, Inc. (Cambridge, MA) | 2036-05-18 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for BAVENCIO
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2720935 | Start Trial |
| Canada | 2808211 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2015136541 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
